Pathophysiology of Heparin-Induced Thrombocytopenia
Tóm tắt
Objective.—This review of heparin-induced thrombocytopenia (HIT), the most frequent and dangerous side effect of heparin exposure, covers the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of this disease syndrome.
Data Sources and Study Selection.—Current consensus of opinion is given based on literature reports, as well as new information where available. A comprehensive analysis of the reasons for discrepancies in incidence numbers is given. The currently known mechanism is that HIT is mediated by an antibody to the complex of heparin–platelet factor 4, which binds to the Fc receptor on platelets. New evidence suggests a functional heterogeneity in the anti-heparin-platelet factor 4 antibodies generated to heparin, and a “superactive” heparin-platelet factor 4 antibody that does not require the presence of heparin to promote platelet activation or aggregation has been identified. Up-regulation of cell adhesion molecules and inflammatory markers, as well as preactivation of platelets/endothelial cells/leukocytes, are also considered to be related to the pathophysiology of HIT. Issues related to the specificity of currently available and new laboratory assays that support a clinical diagnosis are addressed in relation to the serotonin-release assay. Past experience with various anticoagulant treatments is reviewed with a focus on the recent successes of thrombin inhibitors and platelet GPIIb/IIIa inhibitors to combat the platelet activation and severe thrombotic episodes associated with HIT.
Conclusions.—The pathophysiology of HIT is multifactorial. However, the primary factor in the mediation of the cellular activation is due to the generation of an antibody to the heparin-platelet factor 4 complex. This review is written as a reference for HIT research.
Từ khóa
Tài liệu tham khảo
Davey, 1968, Effect of injected heparin on platelet levels in man., J Clin Pathol, 2, 55, 10.1136/jcp.21.1.55
Zucker, 1977, Biological aspects of heparin action: heparin and platelet function., Fed Proc, 36, 47
Fabris, 1983, Normal and low molecular weight heparins: interaction with human platelets., Eur J Clin Invest, 13, 135, 10.1111/j.1365-2362.1983.tb00078.x
Fondu, 1995, Heparin-associated thrombocytopenia., Acta Clin Belg, 50, 343, 10.1080/17843286.1995.11718474
Chong, 1995, Heparin-induced thrombocytopenia., Br J Haematol, 89, 431, 10.1111/j.1365-2141.1995.tb08346.x
Warkentin, 1998, Heparin-induced thrombocytopenia: toward consensus., Thromb Haemost, 79, 1, 10.1055/s-0037-1614206
Chong, 1992, Heparin-induced thrombocytopenia., Aust N Z J Med, 22, 145, 10.1111/j.1445-5994.1992.tb02796.x
Warkentin, 1996, A 14-year study of heparin-induced thrombocytopenia., Am J Med, 101, 502, 10.1016/S0002-9343(96)00258-6
Magnani, 1993, Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org10172)., Thromb Haemost, 70, 554, 10.1055/s-0038-1649626
Schmitt, 1993, Heparin-associated thrombocytopenia: a critical review and pooled analysis., Am J Med Sci, 305, 208, 10.1097/00000441-199304000-00003
Nelson, 1978, Heparin-induced thrombocytopenia., Arch Intern Med, 138, 548, 10.1001/archinte.1978.03630280030014
Powers, 1979, Thrombocytopenia found uncommonly during heparin therapy., JAMA, 241, 2396, 10.1001/jama.1979.03290480030018
Powers, 1984, Studies of the frequency of heparin-associated thrombo-cytopenia., Thromb Res, 33, 439, 10.1016/0049-3848(84)90083-5
Eika, 1980, Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin., Scand J Haematol, 25, 19, 10.1111/j.1600-0609.1981.tb01359.x
Ansell, 1980, Heparin-induced thrombocytopenia: a prospective study., Thromb Haemost, 43, 61, 10.1055/s-0038-1650013
Kwaan, 1981, Incidence of thrombocytopenia during therapy with bovine lung and porcine gut heparin preparations., Thromb Haemost, 46, A680
Weitberg, 1982, Effect of low dose heparin on the platelet count., South Med J, 75, 190, 10.1097/00007611-198202000-00018
Bailey, 1986, Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin., Drug Intell Clin Pharm, 20, 374, 10.1177/106002808602000509
Bell, 1976, Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients., Ann Intern Med, 85, 155, 10.7326/0003-4819-85-2-155
Bell, 1980, Heparin-associated thrombocytopenia: a comparison of three heparin preparations., N Engl J Med, 303, 902, 10.1056/NEJM198010163031602
Malcolm, 1978, Thrombocytopenia induced by low-dose subcutaneous heparin., Lancet, I, 44
Malcolm, 1979, Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin., Can Med Assoc J, 120, 1086
Holm, 1980, Thrombocytes and treatment with heparin from porcine mucosa., Scand J Haematol, 36, 81, 10.1111/j.1600-0609.1980.tb02515.x
Gallus, 1980, Heparin-associated thrombocytopenia: a case report and prospective study., Aust N Z J Med, 10, 25, 10.1111/j.1445-5994.1980.tb03414.x
Romeril, 1982, Heparin-induced thrombocytopenia: a case report and a prospective study., N Z Med J, 95, 267
Cipolle, 1983, Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients., Ther Drug Monit, 5, 205, 10.1097/00007691-198306000-00010
Green, 1984, Thrombocytopenia in a prospective, randomised, double-blind trial of bovine and porcine therapy., Am J Med Sci, 288, 60, 10.1097/00000441-198409000-00003
Jonson, 1984, Heparin-induced thrombocytopenia: a prospective study., Am J Hematol, 17, 349, 10.1002/ajh.2830170404
Ansell, 1985, Heparin-induced thrombocytopenia: what is its real frequency?, Chest, 66, 878, 10.1378/chest.88.6.878
Kakkasseril, 1985, Heparin-induced thrombocytopenia: a prospective study of 142 patients., J Vasc Surg, 2, 382, 10.1016/0741-5214(85)90089-8
Ayars, 1980, Incidence of thrombocytopenia in medical patients on “mini-dose” heparin prophylaxis [letter to editor]., Am Heart J, 99, 816, 10.1016/0002-8703(80)90639-0
Warkentin, 1999, Heparin-induced thrombocytopenia: a clinicopathologic syndrome., Thromb Haemost, 82, 439, 10.1055/s-0037-1615864
Fabris, 1997, Heparin-induced thrombocytopenia: prevalence in a large cohort of patients and confirmed role of PF4-heparin complex as the main antigen for antibodies., Clin Appl Thromb Hemost, 3, 203, 10.1177/107602969700300309
Wallis, 1999, Failure of early heparin cessation as treatment of heparin-induced thrombocytopenia., Am J Med, 106, 629, 10.1016/S0002-9343(99)00124-2
Kappers-Klunne, 1997, Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases., Br J Haematol, 96, 442, 10.1046/j.1365-2141.1997.d01-2056.x
Levy, 1991, Thrombocytopenia due to a low molecular weight heparin during treatment with hypotensive and diuretics drugs., Ann Fr Anesth Reanim, 10, 586
Elalamy, 1997, A fatal low molecular weight heparin-associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test., Blood Coagul Fibrinolysis, 7, 665, 10.1097/00001721-199610000-00001
Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low molecular weight or unfractionated heparin., N Engl J Med, 332, 1330, 10.1056/NEJM199505183322003
Rhodes, 1973, Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestation., Surg Gynecol Obstet, 136, 409
Green, 1978, Heparin immune thrombo-cytopenia: evidence for a heparin-platelet complex as the antigenic determinant., J Lab Clin Med, 91, 167
Greinacher, 1992, Heparin-associated thrombocytopenia: the antibody is not heparin specific., Thromb Haemost, 67, 545, 10.1055/s-0038-1648491
Greinacher, 1993, Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides., Br J Haematol, 84, 711, 10.1111/j.1365-2141.1993.tb03150.x
Kelton, 1994, Immuno-globulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4., Blood, 83, 3232, 10.1182/blood.V83.11.3232.3232
Gruel, 1993, Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia., Thromb Haemost, 70, 374, 10.1055/s-0038-1649587
Lynch, 1985, Heparin-associated thrombocytopenia: antibody binding specificity to platelet antigens., Blood, 5, 1176, 10.1182/blood.V66.5.1176.1176
Amiral, 1992, Platelet factor 4 complexed to heparin is the target for antibodies in heparin-induced thrombocytopenia., Thromb Haemost, 68, 95, 10.1055/s-0038-1656329
Amiral, 1998, The biological basis of immune heparin-induced thrombocytopenia., Platelets, 9, 77, 10.1080/09537109876843
Greinacher, 1994, Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen., Thromb Haemost, 71, 247
Amiral, 1995, Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases., Thromb Haemost, 73, 21, 10.1055/s-0038-1651670
Visentin, 1994, Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells., J Clin Invest, 93, 81, 10.1172/JCI116987
Walenga, 1996, Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents., Clin Appl Thromb Hemost, 2, S21
Greinacher, 1995, Antigen generation in heparin-associated thrombocytopenia: the non-immunologic type and the immunologic type are closely linked in their pathogenesis., Semin Thromb Hemost, 21, 106, 10.1055/s-2007-1000384
Baglin, 1997, Heparin-induced thrombocytopenia syndrome (HIT): diagnosis and treatment., Platelets, 8, 72
Adelman, 1989, Heparin-associated thrombocytopenia: observations on the mechanism of platelet aggregation., J Lab Clin Med, 113, 104
Anderson, 1995, The Fc receptor for immunoglobulin G (Fcγ RIIa) on human platelets., Semin Thromb Hemost, 21, 1, 10.1055/s-2007-1000374
Kelton, 1988, Heparin-induced thrombocytopenia: laboratory studies., Blood, 723, 925, 10.1182/blood.V72.3.925.bloodjournal723925
Chong, 1989, Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets., Br J Haematol, 73, 235, 10.1111/j.1365-2141.1989.tb00258.x
Burgess, 1995, Single amino acid mutation of Fcγ receptor is associated with the development of heparin induced thrombocytopenia., Br J Haematol, 91, 761, 10.1111/j.1365-2141.1995.tb05383.x
Arepally, 1997, FcγRIIa His/Arg 131 polymorphism subclass-specific IgG anti-heparin/PF4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis., Blood, 89, 370, 10.1182/blood.V89.2.370
Horne, 1998, Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into mechanism of heparin-induced thrombocytopenia., Am J Hematol, 58, 24, 10.1002/(SICI)1096-8652(199805)58:1<24::AID-AJH5>3.0.CO;2-2
Suh, 1997, Characterization of the humoral immune response in heparin-induced thrombocytopenia., Am J Hematol, 54, 196, 10.1002/(SICI)1096-8652(199703)54:3<196::AID-AJH4>3.0.CO;2-R
Amiral, 1996, Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular weight heparin., Am J Hematol, 52, 90, 10.1002/(SICI)1096-8652(199606)52:2<90::AID-AJH4>3.0.CO;2-0
Amiral, 1996, Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia., Br J Haematol, 92, 954, 10.1046/j.1365-2141.1996.407945.x
Visentin, 1999, Heparin-induced thrombocytopenia: molecular pathogenesis., Thromb Haemost, 82, 448, 10.1055/s-0037-1615865
Blank, 1997, Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin., Clin Exp Immunol, 108, 333, 10.1046/j.1365-2249.1997.d01-1008.x
Ahmad, 1999, Lack of thrombocytopenic response after low molecular weight heparins usage is due to the generation of non-functional anti-heparin-platelet factor 4 antibodies [abstract]., Blood, 94, 624a
Ahmad, 1999, Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome., Clin Appl Thromb Hemost, 5, S32, 10.1177/10760296990050S107
Fareed, 1999, Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation., Clin Appl Thromb Hemost, 5, S38, 10.1177/10760296990050S108
Mikhailidis, 1997, Pathophysiology of heparin-induced thrombocytopenia (HIT)., Platelets, 8, 66
Boshkov, 1993, Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies., Br J Haematol, 84, 322, 10.1111/j.1365-2141.1993.tb03072.x
Sallah, 1997, Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment., Thromb Haemost, 78, 785, 10.1055/s-0038-1657628
Nand, 1997, Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated in a single institution., Am J Hematol, 56, 12, 10.1002/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5
Hach-Wunderle, 1994, Heparin-associated thrombosis despite normal platelet counts., Lancet, 344, 469, 10.1016/S0140-6736(94)91797-3
Weismann, 1958, Arterial embolism occurring during systemic heparin therapy., Arch Surg, 76, 219, 10.1001/archsurg.1958.01280200041005
Magnani, 1997, Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia., Platelets, 8, 74
Sheridan, 1986, A diagnostic test for heparin-induced thrombocytopenia., Blood, 67, 27, 10.1182/blood.V67.1.27.27
Greinacher, 1994, Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay., Transfusion, 34, 381, 10.1046/j.1537-2995.1994.34594249047.x
Warkentin, 1992, Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia., J Lab Clin Med, 120, 371
Walenga, 1999, Laboratory diagnosis of heparin-induced thrombocytopenia., Clin Appl Thromb Hemost, 5, S21, 10.1177/10760296990050S105
Walenga, 1999, Laboratory tests for heparin-induced thrombocytopenia: a multicenter study., Semin Hematol, 36, 22
Greinacher, 1991, A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia., Thromb Haemost, 66, 734, 10.1055/s-0038-1646493
Amiral, 1997, Diagnostic tests in heparin-induced thrombocytopenia., Platelets, 8, 68
Teitel, 1996, A bioluminescent adenosine nucleotide release assay for the diagnosis of heparin-induced thrombocytopenia., Thromb Haemost, 76, 479, 10.1055/s-0038-1650606
Tomer, 1997, A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia., Br J Haematol, 98, 648, 10.1046/j.1365-2141.1997.2613077.x
Jeske, 1997, Effect of glycoprotein IIb/IIIa antagonists on the HIT serum-induced activation of platelets., Thromb Res, 88, 271, 10.1016/S0049-3848(97)00254-5
Leach, 1997, Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays., Br J Haematol, 97, 755, 10.1046/j.1365-2141.1997.1472960.x
Arepally, 1995, Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia., Am J Clin Pathol, 104, 648, 10.1093/ajcp/104.6.648
Look, 1997, Heparin-induced platelet aggregation vs. platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis., Am J Clin Pathol, 108, 78, 10.1093/ajcp/108.1.78
Bauer, 1997, Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery., Circulation, 95, 1242, 10.1161/01.CIR.95.5.1242
Walenga, 1999, Laboratory tests for the diagnosis of heparin-induced thrombocytopenia., Semin Thromb Hemost, 25, 43
Walenga, 1997, Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome., Clin Appl Thromb Hemost, 3, S53, 10.1177/1076029697003001S08
Kelton, 1996, Heparin-induced thrombocytopenia: what the serologists have taught us., J Lab Clin Med, 128, 346, 10.1016/S0022-2143(96)80003-5
Amiral, 1996, Presence of autoantibodies to interleukin 8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia., Blood, 88, 410, 10.1182/blood.V88.2.410.bloodjournal882410
Izban, 1999, Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia., Semin Thromb Hemost, 25, 51
Nguyen, 1995, Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia., Thromb Haemost, 74, 804, 10.1055/s-0038-1649823
Wallis, 1999, Safety of warfarin anticoagulation on patients with heparin-induced thrombocytopenia., Chest, 116, 1333, 10.1378/chest.116.5.1333
Keeling, 1994, Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG10172 in patients with heparin-induced thrombocytopenia., Br J Haematol, 86, 425, 10.1111/j.1365-2141.1994.tb04760.x
Schiele, 1995, Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia., Am J Hematol, 50, 20, 10.1002/ajh.2830500105
Lewis, 1997, Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome., Semin Thromb Hemost, 23, 197, 10.1055/s-2007-996091
Demers, 1991, Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia., Blood, 78, 2194, 10.1182/blood.V78.9.2194.2194
Bouvier, 1988, Treatment of serious heparin induced thrombocytopenia by plasma exchange: report of 4 cases., Thromb Res, 51, 355, 10.1016/0049-3848(88)90111-9
Frame, 1989, Correction of severe heparin-induced thrombocytopenia with intravenous immunoglobulin., Ann Intern Med, 111, 946, 10.7326/0003-4819-111-11-946
Harenberg, 1997, Anticoagulation in patients with heparin-induced thrombocytopenia type II., Semin Thromb Hemost, 23, 189, 10.1055/s-2007-996090
Denton, 1983, Binding of platelet factor 4 to heparin oligosaccharides., Biochem J, 209, 455, 10.1042/bj2090455
Kikta, 1993, Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?, Surgery, 114, 705
Haas, 1999, Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors., Clin Appl Thromb Hemost, 5, 52, 10.1177/107602969900500111
Luzzatto, 1995, Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use., Thromb Haemost, 74, 1607, 10.1055/s-0038-1649991
Ahmad, 1999, Synthetic pentasaccharides do not cause platelet activation by anti-heparin-platelet factor 4 antibodies., Clin Appl Thromb Hemost, 5, 259, 10.1177/107602969900500410
Chong, 1995, Comment on “Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.”., Br J Haematol, 90, 970, 10.1111/j.1365-2141.1995.tb05230.x
Nurmohamed, 1997, Low molecular weight heparin(oid)s: clinical investigation and practical recommendations., Drugs, 53, 736, 10.2165/00003495-199753050-00002
Tardy-Poncet, 1995, Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome., Br J Haematol, 90, 969, 10.1111/j.1365-2141.1995.tb05229.x
Tardy, 1998, Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses., Thromb Haemost, 80, 530, 10.1055/s-0037-1615249
Lewis, Preliminary results of a prospective randomized controlled trial of argatroban vs. conventional therapy for heparin-induced thrombocytopenia.
Matthai, 1999, Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia., Semin Thromb Hemost, 25, 57
Greinacher, 1999, Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study., Circulation, 99, 73, 10.1161/01.CIR.99.1.73
Beijering, 1996, Clinical applications of new antithrombotic agents., Ann Hematol, 72, 177, 10.1007/s002770050158
Walenga, 1999, Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT., Semin Thromb Hemost, 25, 77
Jeske, 1998, Inhibition of platelet activation in HIT: thrombin inhibitors vs. antiplatelet agents [abstract]., Blood, 92, 180a
Greinacher, 1999, Treatment of heparin-induced thrombocytopenia., Thromb Haemost, 82, 457, 10.1055/s-0037-1615866
Liem, 1997, The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies., J Vasc Surg, 25, 124, 10.1016/S0741-5214(97)70328-8
Fareed, 1999, Immunosuppression results in a reduction in anti-heparin-platelet factor 4 antibodies: implications in the management of heparin-induced thrombocytopenia [abstract]., Blood, 94, 19a